AveXis Inc. (NASDAQ:AVXS) shares traded down 5.6% on Monday . The stock traded as low as $35.17 and last traded at $35.51, with a volume of 144,118 shares. The stock had previously closed at $37.63.

Several research firms have commented on AVXS. Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. Goldman Sachs Group Inc. raised their target price on AveXis from $28.00 to $47.00 and gave the company a “buy” rating in a research note on Friday, May 13th. Jefferies Group downgraded AveXis from a “buy” rating to a “hold” rating and lifted their price target for the stock from $39.00 to $42.00 in a research note on Wednesday, June 22nd. They noted that the move was a valuation call. Wells Fargo & Co. initiated coverage on AveXis in a research note on Friday, July 15th. They issued a “market perform” rating for the company. Finally, Chardan Capital reiterated a “buy” rating and issued a $60.00 price target on shares of AveXis in a research note on Monday, May 9th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $43.80.

The stock’s market cap is $777.38 million. The firm has a 50-day moving average of $38.49 and a 200-day moving average of $31.17.

AveXis (NASDAQ:AVXS) last announced its earnings results on Thursday, May 12th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.89. On average, equities analysts anticipate that AveXis Inc. will post ($3.65) earnings per share for the current year.

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.